Matrifen

Fentanyl, the active ingredient in Matrifen, is an opioid analgesic presented as a transdermal patch for transdermal use. It treats severe chronic pain and cancer‑related pain in patients who require continuous opioid therapy.

GNH USA supplies Matrifen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Fentanyl is an opioid analgesic used for managing severe pain conditions.

- Severe chronic non‑cancer pain: provides continuous opioid delivery to maintain consistent analgesia. - Cancer‑related pain: offers sustained relief for patients with advanced malignancies. - Breakthrough pain (as adjunct to other opioid therapy): supplements baseline analgesia during episodic pain spikes.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel motility. - Drowsiness: increased sleepiness. - Dizziness: sensation of light‑headedness. - Sweating: excessive perspiration at the application site. - Application site reactions: redness or itching where the patch is placed.

Serious or Rare Side Effects: - Respiratory depression: dangerously slowed breathing. - Severe hypotension: marked drop in blood pressure. - Adrenal insufficiency: impaired cortisol production. - Skin necrosis: tissue death at the patch site. - Opioid dependence or abuse: risk of addiction. - Anaphylaxis: life‑threatening allergic reaction.

Before prescribing Matrifen, clinicians should consider several safety measures. - Assess pain severity and opioid tolerance: ensure the patient requires continuous opioid therapy. - Evaluate respiratory function: avoid use in patients with significant respiratory depression. - Review hepatic and renal function: dose adjustments may be needed in impairment. - Monitor for signs of addiction or misuse: implement appropriate risk mitigation. - Counsel on proper application: rotate patch sites to minimize skin irritation. - Store at room temperature: keep patch in original packaging, protect from moisture and direct sunlight.

Fentanyl may interact with other medications, requiring careful management.

Major Interactions (Avoid): - Respiratory depressants (e.g., benzodiazepines, barbiturates): risk of profound respiratory depression. - MAO inhibitors: may cause severe hypotension and serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase fentanyl plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce fentanyl effectiveness. - Other CNS depressants (e.g., alcohol, antihistamines): may enhance sedation and dizziness.